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Abstract: Secondhand smoke (SHS) is a major contributor to indoor air pollution. Because 
it contains respiratory irritants, it may adversely inﬂ  uence the clinical course of persons with 
chronic obstructive pulmonary disease (COPD). We used data from nonsmoking members of 
the FLOW cohort of COPD (n = 809) to elucidate the impact of SHS exposure on health status 
and exacerbations (requiring emergency department visits or hospitalization). SHS exposure was 
measured by a validated survey instrument (hours of exposure during the past week). Physical 
health status was measured by the SF-12 Physical Component Summary Score and disease-
speciﬁ  c health-related quality of life (HRQL) by the Airways Questionnaire 20-R. Health care 
utilization for COPD was determined from Kaiser Permanente Northern California computerized 
databases. Compared to no SHS exposure, higher level SHS exposure was associated with poorer 
physical health status (mean score decrement −1.78 points; 95% conﬁ  dence interval [CI] −3.48 
to −0.074 points) after controlling for potential confounders. Higher level SHS exposure was 
also related to poorer disease-speciﬁ  c HRQL (mean score increment 0.63; 95% CI 0.016 to 
1.25) and less distance walked during the Six-Minute Walk test (mean decrement −50 feet; 
95% CI −102 to 1.9). Both lower level and higher level SHS exposure was related to increased 
risk of emergency department (ED) visits (hazard ratio [HR] 1.40; 95% CI 0.96 to 2.05 and 
HR 1.41; 95% CI 0.94 to 2.13). Lower level and higher level SHS exposure were associated 
with a greater risk of hospital-based care for COPD, which was a composite endpoint of either 
ED visits or hospitalizations for COPD (HR 1.52; 95% CI 1.06 to 2.18 and HR 1.40; 95% CI 
0.94 to 2.10, respectively). In conclusion, SHS was associated with poorer health status and a 
greater risk of COPD exacerbation. COPD patients may comprise a vulnerable population for 
the health effects of SHS.
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Chronic obstructive pulmonary disease (COPD) is a common and disabling condition. 
Although the major cause of COPD is direct cigarette smoking, other factors may 
inﬂ  uence the clinical course of established disease. Emerging evidence suggests that 
the indoor environment may be one of these factors. A cross-sectional study of COPD 
patients found that higher indoor level of ﬁ  ne particles (PM2.5) was associated with 
greater respiratory symptoms.1 Other recent data indicate that combustion of wood 
or charcoal for heating or cooking in the home may contribute to COPD morbidity.2 
Despite these intriguing initial observations, scant knowledge exists about the indoor 
environment and COPD.
Secondhand smoke (SHS) is a major source of indoor pollution. Existing evidence 
indicates that SHS exposure is an important cause of asthma exacerbation among 
children and, to a lesser extent, adults.3–5 In COPD, however, there are few studies that International Journal of COPD 2009:4 170
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address the impact of SHS exposure on clinical course.1,6,7 
We used data from a large prospective cohort study of COPD 
to evaluate the impact of SHS exposure on health status and 
disease exacerbation.
Methods
Overview
The FLOW (Function, Living, Outcomes, and Work) study 
of COPD is an ongoing prospective cohort study of adult 
members of an integrated health care delivery system with 
a physician’s diagnosis of COPD. The long-term goal is to 
determine what factors are responsible for the development 
of disability in COPD. At baseline assessment, we conducted 
structured telephone interviews that ascertained COPD-
related health status, sociodemographic characteristics, and 
SHS exposure. Research clinic visits included spirometry 
and other physical assessments. In this report, we evaluated 
the impact of recent SHS exposure on health status and the 
future risk of emergency health care utilization for COPD. 
The study was approved both by the University of California, 
San Francisco Committee on Human Research and the Kaiser 
Foundation Research Institute’s institutional review board 
and all participants provided written informed consent.
Subject recruitment
We studied adult members of Kaiser Permanente Medical 
Care Program (KPMCP), the nation’s largest nonproﬁ  t 
managed care organization. In northern California, the 
KPMCP provides the full spectrum of primary-to-tertiary 
care to approximately 3.2 million members. In northern 
California, KPMCP’s share of the regional population 
ranges from 25 to 30%.8 The demographic characteristics 
of KPMCP members are similar to the overall northern 
California population, except for the extremes of income 
distribution.9
Recruitment methods have been previously reported in 
detail.10,11 We identiﬁ  ed all adult KPMCP members who 
were recently treated for COPD using a previously described 
approach. The age range was restricted to 40–65 years 
because a key study outcome includes work disability.12 
Using KPMCP computerized databases, we identified 
all subjects who met each of two criteria: one based on 
health care utilization and the second based on medication 
prescribing. The health care utilization criterion was one 
or more ambulatory visits, emergency department (ED) 
visits, or hospitalizations with a principal International 
Classiﬁ  cation of Disease (ICD-9) diagnosis code for COPD 
(chronic bronchitis [491], emphysema [492], or COPD 
[496] during a recent 12-month time period. The medica-
tion criterion was two or more prescriptions for a COPD-
related medication during a 12-month window beginning 
six months before the index utilization date and ending six 
months after index date. The criterion medications included: 
inhaled anticholinergic medications, inhaled beta agonists, 
inhaled corticosteroids, or theophylline. Based on medical 
record review, we demonstrated that this algorithm is a valid 
method for identifying adults with COPD.12 To facilitate 
attendance at the research clinic, we restricted the sample 
to persons living within a 30 mile geographic radius of the 
research clinic where the study examinations took place.
Persons identiﬁ  ed by the algorithm who were no longer 
KPMCP members or who had moved away were considered 
ineligible for study. The primary care physicians for all 
patients were contacted and given the opportunity to decline 
contact of any identiﬁ  ed patients under their care. Potential 
subjects were then contacted by a letter describing the study 
and given an opportunity to decline participation. Those 
not declining were contacted by telephone to arrange an 
interview. At the end of the interview, subjects were invited 
to participate in the research clinic visit. Persons who were 
found at the time of interview to have severe communication 
difﬁ  culties attributable to advanced dementia or aphasia 
were excluded.
A total of 5,800 subjects were initially identiﬁ  ed using 
the computerized algorithm. Of these, 298 died before 
they could be recruited into the study. Another 1,011 did 
not meet study inclusion criteria or were excluded at the 
time of interview contact as noted above. The completion 
rate for structured telephone interviews was 2,310 out of a 
remaining eligible group of 4,491 (51%). This is comparable 
to our earlier cohort study of adult asthma conducted at 
KPMCP and compares favorably for other survey-based 
epidemiologic studies conducted in the US.13,14 Among the 
2,310 respondents, 112 were not eligible for the clinic visit 
and 1,216 completed the research clinic visit (55% of those 
interviewed and eligible). An additional 10 subjects were 
excluded because they did not meet the GOLD criteria for 
COPD after interviews and spirometry were performed.15 
Four additional subjects were excluded from this analysis 
because they could not perform spirometry due to previous 
tracheostomy placement. Ultimately, there were 1,202 
subjects with COPD who completed both interviews and 
research clinic visits. Previous reports compared respondents 
and nonrespondents.10,11,16
The current analysis of SHS exposure and COPD 
outcomes was restricted to current nonsmokers (n = 809).International Journal of COPD 2009:4 171
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Structured telephone interviews
Each subject underwent a 30–40 minute structured telephone 
interview that used customized computer-assisted telephone 
interview (CATI) software. Interviews ascertained sociode-
mographic characteristics. Cigarette smoking was measured 
using questions developed for the National Health Interview 
Survey.17 As in previous studies, we deﬁ  ned educational 
attainment as high school or less, some college, or college/
graduate degree.18 Race/ethnicity was deﬁ  ned based on self-
report as a series of categories: white/non-Hispanic, Black, 
Asian or Paciﬁ  c Islander, Hispanic or Latino, and other.18 
For analysis, we classiﬁ  ed subjects as white, non-Hispanic 
vs all others.
SHS exposure measurement
We previously developed and validated a survey instrument 
that assesses recent SHS exposure for adults with obstructive 
lung disease.19 The instrument ascertains exposure during the 
past seven days in seven microenvironments: the respondent’s 
home, another person’s home, traveling in a car or another 
vehicle, workplace (including dedicated smoking areas), bars 
and nightclubs, outdoor locations, and other locations. In each 
area, the instrument queries the total duration (in hours) of 
exposure during the past seven days. Based on the distribution 
of responses, we deﬁ  ned three ordinal categories of exposure: 
no exposure, lower level exposure (up to 1 hour/week), and 
higher level ( 1 hour/week) exposure. The lower level and 
higher level exposure categories were divided at the median 
among those with any exposure to ensure approximately 
equal numbers of subjects in each group.
Study outcomes: Health status measures
We used a combined approach with disease-speciﬁ  c and 
generic health status measurements to assess COPD-related 
health status. At the time of telephone interview, generic 
physical health status was measured with the Short Form 
(SF)-12 Physical Component Summary (PCS) score. The 
SF-12 is derived from the Medical Outcomes Study SF-36 
instrument, which is the most widely used measure of generic 
health status. The SF-36 has been extensively validated in 
the general population20 and among adults with COPD.21 
Deﬁ  ned from the eight SF-36 subscales by factor analysis, 
the PCS score reﬂ  ects an underlying physical dimension 
of physical HRQL.22 Higher scores reﬂ  ect more favorable 
health states.
We used the Airways Questionnaire 20 revised (AQ-20R) 
to measure disease-speciﬁ  c HRQL.23,24 This validated instru-
ment has excellent psychometric properties for assessing 
HRQL in persons with airway disease, including COPD. 
Higher scores correspond to poorer HRQL.23,25
Submaximal exercise performance was measured using 
the Six-Minute Walk Test, which was developed by Guyatt 
and has been widely used in studies of COPD.26,27 We used a 
standardized ﬂ  at, straight course of 30 meters in accordance 
with American Thoracic Society (ATS) Guidelines.28 Sub-
jects who routinely used home oxygen or who had a resting 
oxygen saturation  90% were supplied with supplemental 
oxygen during the test. Every two minutes, the technician 
used standardized phrases to encourage effort, as recom-
mended by the ATS guidelines. The primary outcome mea-
sured was the total distance walked in six minutes.
Longitudinal outcomes: Disease 
exacerbation
We used ED visits and hospitalization for COPD as proxy 
measures of severe disease exacerbation. These outcomes were 
ascertained during prospective follow-up, after completion 
of baseline interviews. COPD-related hospitalization was 
deﬁ  ned as those with a principal ICD-9 discharge diagnosis 
code for COPD (491, 492, or 496). COPD-related ED visits 
were identiﬁ  ed as those with an ICD-9 code for COPD. In 
contrast to hospital discharge diagnoses, ED visits do not 
distinguish primary or secondary diagnoses within the Kaiser 
system. A composite outcome for hospital-based care was 
deﬁ  ned as either an ED visit or hospitalization for COPD. 
The median duration of follow-up was 2.1 years (25th–75th 
interquartile range 1.7 to 2.6 years). During the follow-up 
period, there were 50 hospitalizations and 153 ED visits 
for COPD.
Measurement of disease severity
Disease severity can confound the study of SHS exposure. 
Although SHS exposure may increase COPD severity, per-
sons with greater COPD-related breathing symptoms might 
selectively avoid exposure (the “healthy passive smoker” 
effect). Consequently, we explicitly considered disease 
severity in our analysis.
To measure disease severity, we used a combined 
approach. We employed a disease-speciﬁ  c COPD severity 
score that we had previously developed and validated for use 
in epidemiologic and outcomes research.29 Based on survey 
responses, the COPD severity score is comprised of ﬁ  ve 
overall aspects of COPD severity: respiratory symptoms, 
systemic corticosteroid use, other COPD medication use 
(including inhaled corticosteroids), previous hospitalization 
or intubation for respiratory disease, and home supplemental International Journal of COPD 2009:4 172
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oxygen use. Each item was weighted based on clinical aspects 
of the disease and its expected contribution to overall COPD 
severity. Possible total scores range from 0 to 35, with higher 
scores reﬂ  ecting more severe COPD.
We also used the validated BODE index, which is a 
multi-modal measure of disease severity.30 The BODE index 
is based on the body mass index (B), the degree of airﬂ  ow 
obstruction (O) measured by forced expiratory volume in 
1 second (FEV1), grade of dyspnea (D) assessed by the 
modiﬁ  ed MRC Dyspnea Scale, and exercise capacity (E) 
measured by the Six-Minute Walk Test. Each component is 
assigned a speciﬁ  c score and the total score ranges from 0 to 
10 points (higher scores indicate greater severity. The BODE 
index predicts death and other poor outcomes in COPD.30–32
To assess respiratory impairment, which is a component 
of the BODE index, we conducted spirometry according 
to ATS Guidelines.33,34 We used the EasyOne™ Frontline 
spirometer (ndd Medical Technologies, Chelmsford, MA), 
which is known for its reliability, accuracy, and durability.35,36 
The Easyone spirometer has been used by two large scale 
multicenter international epidemiologic studies of COPD: the 
BOLD Study (Burden of Obstructive Lung Disease) and the 
Platino Study (Latin American Project for the Investigation 
of Obstructive Lung Disease).36,37 Percent predicted values 
were calculated using predictive equations derived from 
NHANES III.38
Statistical analysis
Statistical analysis was conducted using SAS software, 
version 9.1 (SAS Institute, Inc., Cary, NC). The relationship 
between SHS exposure category (none, lower level, and 
higher level) and variables of study interest was examined 
using the chi-square test for categorical variables and analysis 
of variance for continuous variables. We used multivariable 
linear regression analysis to elucidate the association 
between SHS exposure categories and health status out-
comes (physical health status, disease-speciﬁ  c quality of life, 
and distance walked in six minutes). In these analyses, we 
controlled for key variables that might confound the relation-
ship between SHS exposure and health outcomes, including 
age, sex, race, educational attainment, marital status, COPD 
severity, and previous smoking history (all subjects were 
current nonsmokers).39,40 We also performed a secondary 
analysis using backwards selection to identify covariates after 
forcing the SHS exposure variables into the model (p value 
cut-off for covariate removal was 0.10). In all analyses, a 
two-tailed p value of 0.05 was considered to represent the 
conventional threshold of statistical signiﬁ  cance.
We used Cox proportional hazards regression to elucidate 
the impact of SHS exposure on the prospective risk of ED 
visits, hospitalizations, and hospital-based care (composite 
of ED visits and hospitalizations). Control for confounding 
variables was performed as described for linear regression 
analysis (above). The proportional hazards assumption was 
veriﬁ  ed by evaluating interaction terms between time and SHS 
exposure (p   0.40 in all cases, indicating no violation).
We also carried out a secondary analysis to further control 
for confounding. We used logistic regression analysis to 
create propensity scores for SHS exposure. The propensity 
score is the probability of SHS exposure based on known 
personal characteristics. To control for confounding, we 
then re-estimated the linear regression analysis and Cox 
proportional hazards analysis including adjustment for the 
propensity score.41 There was no substantive difference 
compared to the primary analysis (data not shown).
Results
Baseline characteristics and SHS 
exposure
Nearly half of current nonsmokers with COPD reported SHS 
exposure during the past week (n = 364; 45%; 95% conﬁ  dence 
interval [CI] 42 to 49%) (Tables 1 and 2). Of those reporting 
any SHS exposure, 55% and 45% were in the lower level and 
higher level exposure categories, respectively. Females were 
somewhat less likely to report SHS exposure (p = 0.09); there 
was an inverse relationship between educational attainment 
and SHS exposure (p = 0.01) (Table 1). Notably, a history of 
prior smoking and COPD severity (as measured by both the 
COPD severity score and BODE score) were not related to SHS 
exposure status (Table 1). Table 2 provides the distribution of 
self-reported SHS exposure during the past 7 days.
Impact of SHS exposure on health 
status in COPD
Compared to no SHS exposure, higher level SHS exposure 
was associated with poorer physical health status (mean score 
decrement −1.78 points; 95% CI −3.48 to −0.074 points) 
(Table 3). Higher level SHS exposure was also related to poorer 
disease-speciﬁ  c HRQL (mean score increment 0.63; 95% CI 
0.016 to 1.25) and less distance walked during the Six-Minute 
Walk test (mean decrement −50 feet; 95% CI −102 to 1.9). In 
the model using backwards selection to identify covariates, the 
conﬁ  dence interval excluded the no effect level for the high 
level SHS category and distance walked (mean decrement 
−55 feet; −3.4 to −106; p = 0.037).International Journal of COPD 2009:4 173
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Prospective impact of SHS exposure 
and COPD exacerbation
SHS exposure was longitudinally associated with a greater 
risk of COPD exacerbation, as measured by ED visits for 
COPD. Both lower level and higher level SHS exposure 
was related to increased risk of ED visits (hazard ratio [HR] 
1.40; 95% CI 0.96 to 2.05 and HR 1.41; 95% CI 0.94 to 2.13, 
respectively) (Table 4). Although there was no clear relation-
ship between SHS exposure and hospitalization for COPD, 
lower level and higher level SHS exposure were associated 
with a greater risk of hospital-based care for COPD, which 
was a composite endpoint of either ED visits or hospitaliza-
tions for COPD (HR 1.52; 95% CI 1.06 to 2.18 and HR 1.40; 
95% CI 0.94 to 2.10, respectively).
When we redeﬁ  ned SHS exposure as any exposure vs 
none during the past seven days, SHS exposure was associ-
ated with a greater risk of ED visits (HR 1.41; 95% CI 1.02 
to 1.94; p = 0.036) and hospital-based care for COPD (HR 
1.47; 95% CI 1.08 to 2.00; p = 0.015). Although the risk 
estimate for hospitalization was elevated (HR 1.29; 95% 
CI 0.73 to 2.27) the conﬁ  dence interval included the no 
effect level.
Discussion
SHS exposure was common among patients with COPD. 
Nonetheless, exposure intensity was generally low, which 
likely reﬂ  ects the low prevalence of current smoking and the 
statewide workplace smoking ban in California. Despite the 
relatively low intensity of exposure, SHS was associated with 
poorer health status and a greater risk of COPD exacerbation. 
Consequently, patients with COPD appear to be vulnerable 
to adverse health effects of low-level SHS exposure.
Our study adds to the emerging literature that SHS expo-
sure may adversely affect the clinical course of COPD. We 
previously reported in another cohort that short-term SHS 
exposure, as evidenced by urine cotinine, was related to poorer 
COPD severity and health status measures.6 In a previous 
cohort study of adults hospitalized for COPD, self-reported 
SHS exposure was also a risk factor for re-hospitalization.7 
Table 1 Baseline characteristics of the nonsmoking FLOW cohort by SHS exposure status (n = 809)
Characteristic
No SHS exposure 
(n = 445)
Low level SHS 
exposure (n = 200)
High level SHS 
exposure (n = 164)
P value for 
comparison
Age (years) 58 (6.3) 59 (6.1) 59 (5.9) 0.31
Sex (female) 269 (61%) 106 (53%) 86 (52%) 0.088
White, non-Hispanic 304 (68%) 131 (66%) 106 (65%) 0.62
Smoking history
  Never smoked 100 (23%) 37 (19%) 28 (17%) 0.25
  Ex-smoker 348 (78%) 163 (82%) 136 (83%)
Educational attainment 0.014
  High school or less 111 (25%) 46 (23%) 62 (38%)
  Some college 183 (41%) 88 (44%) 61 (37%)
  College or graduate degree 151 (34%) 66 (33%) 41 (25%)
Married or cohabiting 286 (64%) 130 (65%) 113 (69%) 0.56
COPD severity score 10.1 (6.1) 11 .0 (6.5) 10.5 (5.6) 0.71
BODE score 3.0 (2.4) 2.9 (2.5) 2.6 (2.2) 0.23
FEV1 % predicted 62 (23) 62 (24) 65 (22) 0.32
Notes: Results are mean (sd) for age, COPD severity score, and BODE score; n (%) for all others – column proportions are reported.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1 forced expiratory volume in one second; FLOW, Function, Living, Outcomes, and Work study; SHS, 
secondhand smoke.
Table 2 SHS exposure during the past seven days among adults 
with COPD
Group of subjects
Median 
(hours)
25th–75th IQR
(hours)
All subjects (n = 809) 0 0–4.0
Subgroup with any SHS exposure
Entire subgroup (n = 364) 1.0 0.5–3.0
Lower level exposure (n = 200)* 0.7 0.3 to 1.0
Higher level exposure (n = 164) 4.0 2.0–6.0
Notes: *SHS exposure was assessed using a validated survey instrument that 
assessed duration of SHS exposure (hours) during the past seven days in a variety of 
microenvironments. The hours of SHS exposure during the past seven days in each 
microenvironments were summed to calculate the total. Lower level and higher level 
were divided at the median among those with any exposure.
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile 
range; SHS, secondhand smoke.International Journal of COPD 2009:4 174
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Another population-based US study found that self-reported 
SHS exposure was related to a greater risk of “chronic respira-
tory disease exacerbation,” deﬁ  ned as activity limitation or a 
physician visit due to asthma, chronic bronchitis, emphysema, 
or chronic sinusitis.42 More recently, indoor PM2.5 levels, a proxy 
measure of home SHS exposure, was associated with poorer 
disease-speciﬁ  c quality of life among persons with COPD.1 The 
present ﬁ  ndings add signiﬁ  cant additional evidence that SHS 
exposure is deleterious for patients with COPD.
A significant study strength is the large sample of 
clinically well-characterized COPD patients who manifest 
a broad spectrum of disease severity, ranging from mild to 
severe. The cohort is also diverse in terms of gender, race-
ethnicity, and socioeconomic status. Recruitment from a large 
health plan that covers a substantive proportion of the regional 
population helps to ensure generalizability to patients who 
are being treated for COPD in clinical practice.
Our study is also subject to several limitations. Although 
the inclusion criteria required health care utilization for 
COPD, misclassiﬁ  cation of COPD could have occurred. To 
minimize this, our COPD deﬁ  nition required concomitant 
treatment with COPD medications to increase the speciﬁ  city 
of our deﬁ  nition. In addition, all patients had a physician 
diagnosis of COPD and reported having the condition. The 
observed lifetime smoking prevalence was similar to that 
in other population-based epidemiologic studies of COPD, 
supporting the diagnosis of COPD rather than asthma.39,43 We 
also previously demonstrated the validity of our approach 
using medical record review.12 Nonetheless, we acknowledge 
this potential misclassiﬁ  cation as a study limitation.
We used self-reported SHS exposure which could 
have resulted in misclassiﬁ  cation of exposure. The SHS 
survey exposure instrument has been previously validated 
against a direct measurement of exposure.19 Based on our 
previous work, however, we know that self-reported SHS 
exposure tends to underestimate actual exposure.5 To the 
extent that exposure misclassiﬁ  cation is nondifferential with 
respect to respiratory status, the bias would be conservative 
Table 3 Impact of SHS exposure on health status in COPD
SHS exposure category* Health status outcome†
Physical health status Disease-speciﬁ  c HRQL Submaximal exercise performance
Mean points (95% CI) Mean points (95% CI) Mean feet walked in six minutes (95% CI)
None (n = 838) 0 (referent) 0 (referent) 0 (referent)
Lower level SHS exposure (n = 200) 0.007 (−1.56 to 1.57) P = 0.99 0.36 (−0.21 to 0.93) P = 0.22 −0.62 (−49 to 47) P = 0.98
Higher level SHS exposure (n = 164) −1.78 (−3.48 to −0.074) P = 0.041‡‡ 0.63 (0.016 to 1.25) P = 0.04‡‡ −50 (−102 to 1.9) P = 0.059‡‡
Notes: Multivariable linear regression controlling for age, sex, race, educational attainment, smoking history, COPD severity score, and BODE score. Results are mean change 
in health status outcome variable for lower level HS exposure vs none; higher level SHS exposure vs none; *Based on validated survey instrument that assessed duration of 
SHS exposure (hours) during the past seven days in a variety of microenvironments. Lower level and higher level were divided at the median among those with any exposure; 
†Physical health status was assessed using the SF-12 Physical Component Summary Score; Disease-speciﬁ  c health-related quality of life with the Airways Questionnaire 20-
Revised; Submaximal exercise performance with the Six-Minute Walk Test; ‡‡p   0.05 in linear regression analysis using backwards selection (to eliminate covariates with p 
value   0.10).
Abbreviations: CI, conﬁ  dence interval; COPD, chronic obstructive pulmonary disease; HRQL, health-related quality of life; SHS, secondhand smoke.
Table 4 Prospective impact of SHS exposure on emergency health care utilization for COPD
SHS exposure
category*
Emergency department
visit for COPD
Hospitalization
for COPD
Any hospital-based
care for COPD‡
Hazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI)
None (n = 445) 1.0 (referent) 1.0 (referent) 1.0 (referent)
Lower level SHS 
exposure (n = 200)
1.40 (0.96 to 2.05)
P = 0.078
1.37 (0.72 to 2.61)
P = 0.34
1.52 (1.06 to 2.18)
P = 0.023
Higher level SHS 
exposure (n = 164)
1.41 (0.94 to 2.13)
P = 0.097††
1.15 (0.51 to 2.59)
P = 0.73
1.40 (0.94 to 2.10)
P = 0.099‡‡
Notes: Multivariable Cox proportional hazards analysis controlling for age, sex, race, educational attainment, smoking history, COPD severity score, and BODE score. Results 
are hazard ratio for lower level HS exposure vs none; higher level SHS exposure vs none; *Based on validated survey instrument that assessed duration of SHS exposure (hours) 
during the past six days in a variety of microenvironments. Lower level and higher level were divided at the median among those with any exposure; †Emergency department 
visits and hospitalizations for COPD were ascertained from Kaiser Permanente Northern California computerized databases (see Methods); ‡Combined endpoint of either 
hospitalization or emergency department visit for COPD; ††p = 0.08 from Cox model using backwards selection; ‡‡p = 0.085 from Cox model using backwards selection.
Abbreviations: COPD, chronic obstructive pulmonary disease; SHS, secondhand smoke.International Journal of COPD 2009:4 175
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(ie, “towards the null”). If persons with greater disease 
severity were more likely to remember or report SHS 
exposure, the estimates of SHS-related health effects would 
be inﬂ  ated. Because we used two complementary methods to 
control for the effects of disease severity, which included both 
traditional multivariable regression and propensity scoring, 
we explicitly controlled for this possible bias.
In addition, some subjects could have inaccurately 
reported their current personal smoking status. We observed 
no relationship between past smoking and reported SHS 
exposure, which is reassuring that there is no confounding by 
direct personal smoking. We cannot, however, fully exclude 
the possibility of residual confounding.
Selection bias could have been introduced by nonpar-
ticipation in the study. There were some differences among 
subjects who did and did not participate in the interviews 
and clinic visits, but they were modest in scope and not 
likely to affect the relation between SHS exposure and 
health outcomes. Even so, we acknowledge the potential for 
selection bias as a limitation of our study.
In sum, SHS exposure appears to increase the risk of 
adverse health outcomes, including poorer physical health 
status, HRQL, exercise capacity, and disease exacerbation 
resulting in emergency health care utilization. These poor 
health outcomes were observed at low levels of SHS 
exposure. Patients with COPD may comprise a vulnerable 
population who are at especially high risk of the respiratory 
health effects of SHS exposure. Promotion of smoke-free 
indoor environments, including the home and public places, 
will likely beneﬁ  t persons with COPD and other chronic 
respiratory diseases.
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